A double blind, adjuvant controlled, randomized Phase IIb trial to evaluate effectiveness of REMUNE in conjunction with antiretroviral drugs.
Phase of Trial: Phase II
Latest Information Update: 23 Feb 2017
At a glance
- Drugs GP120-depleted HIV-1 vaccine (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics
- Acronyms STIR-2102
- 23 Feb 2017 New trial record.
- 30 Dec 2016 Results published in the Immune Response BioPharma Media Release.
- 30 Dec 2016 Primary endpoint has been met. (CD4 + cell counts and Viral load)